Clinical Trials

Home/Clinical Trials

Stem cell transplants may induce long-term remission of multiple sclerosis

Wednesday, February 1, 2017 Encouraging results help set stage for larger studies. New clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS), an autoimmune disease in which the immune system attacks the central nervous system. “...these

Stem cell therapy trial at Sanford first of its kind in U.S. for shoulder injuries

FDA-approved study explores utility of fat-derived stem cells SIOUX FALLS, S.D. – The first FDA-approved clinical trial of its kind in the United States using a person’s own fat-derived adult stem cells to treat shoulder injuries is available at Sanford Health. The trial opened in December and explores if adipose stem cells, which are taken

Landmark Alzheimer’s prevention trial to evaluate third drug

Effort to study drug's ability to prevent, delay the disease By Tamara Bhandari December 19, 2016 Washington University School of Medicine's Randall J. Bateman, MD, talks with DIAN-TU trial participant Natalie Shriver, of Omaha, about a study to test drugs that may prevent or delay Alzheimer's disease. (Photo: Robert Boston/Washington University School of Medicine) An

Researchers launch first clinical trial for Wolfram syndrome

Many people with rare genetic disease die prematurely by Jim Dryden•November 10, 2016 The drug dantrolene is a muscle relaxant approved to treat patients with cerebral palsy, multiple sclerosis and muscle spasticity. Recent research also suggests it can prevent the destruction of insulin-secreting beta cells in animal models of Wolfram syndrome. Researchers at Washington University

Innovative Regenerative Approach to Healing Diabetic Foot Ulcers Now Being Trialed at Two Additional UK sites

November 8, 2016 LONDON, UNITED KINGDOM and PERTH, AUSTRALIA and NORTHRIDGE, CA--(Marketwired - Nov 8, 2016) - Avita Medical (ASX: AVH), (OTCQX: AVMXY) Two London hospitals join the study to evaluate safety and effectiveness of new approach using ReGenerCell™ Innovative regenerative technology uses patients' own skin cells to close wounds caused by chronic Diabetic Foot

CIRM-Funded Clinical Trial for ALS Given Go Ahead to Treat Patients

October 24, 2016 Oakland, CA – An ingenious method that uses a patient as their own control has been given clearance to start a clinical trial to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. The California Institute for Regenerative Medicine (CIRM) is funding the trial. ALS is a devastating disease that

October 24th, 2016|Categories: ALS, Clinical Trials|Tags: , , |

Stem Cell Agency Spinal Cord Injury Clinical Trial Passes Safety Hurdles

Posted: August 31, 2016 Oakland, CA – A clinical trial using stem cells to treat people with recent spinal cord injuries has cleared two key safety hurdles, and been given approval to expand the therapy to a larger group of patients with a much higher dose of cells. Asterias Biotherapeutics announced that its Data Monitoring

From labs to lives: Self-replicating cells help treat neuro disorders

July 27, 2016 Scientists estimate that human bodies contain anywhere from 75 to 100 trillion cells. And of these cells, there are hundreds of different types. Yet, one cell type in particular has captured the fascination of assistant professor David Brafman: the human pluripotent stem cell (hPSC).Assistant professor David Brafman mentoring biomedical engineering junior Lexi

Napster Co-Founder Funds Immunotherapy Research Project

Wed, 04/13/2016 - 10:00am Ryan Bushey, Digital Editor, R&D Parker (left) made a generous donation to cancer research. (Credit: The Parker Institute)Sean Parker, the entrepreneur behind music-sharing service Napster, is providing a $250 million grant to support a consortium aimed at development of immunotherapy research.This venture, a non-profit named the Parker Institute for Cancer Immunotherapy, will

Stem cell therapy ‘halves number of heart failure deaths’

April 11, 2016 Spectator Health reporter Injecting adult stem cells into the heart could potentially halve the number of deaths from heart failure, a study has suggested. The study, published in the Lancet, found that patients who received the treatment had a 37 per cent lower rate of death and hospitalisation for heart failure-related problems.